Astrana Health stock performance snapshot

Astrana Health (ASTH) has drawn investor attention after a strong recent run, with the stock up 8.9% in the past day, 12.3% over the week, and 42.2% over the past month.

Those short term share price moves sit on top of a much stronger run, with a 90 day share price return of 103.9% and a 1 year total shareholder return of 37.7%. This points to building momentum as investors reassess Astrana Health's growth profile and risks.

If Astrana Health's recent surge has you rethinking your healthcare exposure, it could be a good moment to scan for other opportunities in the sector using our 34 healthcare AI stocks

With Astrana Health trading at $39.30 at an 8% discount to an analyst price target of $42.44, while some models suggest a much steeper intrinsic discount, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 9.2% Overvalued

The most followed Astrana Health narrative pegs fair value at $36.00 using a 7.28% discount rate, below the current $39.30 share price. This sets up a clear valuation gap to interrogate.

Continued transition to full risk, value-based care contracts (now 78% of revenue, up from 60% YoY) is driving recurring, higher-quality revenue streams and improved patient retention. This positions Astrana to benefit from rising demand for coordinated, efficient healthcare as the U.S. population ages, which may support both revenue growth and sustainable margin expansion over time.

Want to see how this value-based care shift feeds into the $36.00 fair value? The narrative leans heavily on rising earnings power, richer margins, and a reset profit multiple that has to line up with those future cash flows.

Result: Fair Value of $36.00 (OVERVALUED)

However, that story can come under pressure if reimbursement from Medicare and Medicaid tightens, or if large acquisitions like Prospect Health prove harder to integrate.

Another View: Cash Flows Paint a Very Different Picture

While the popular narrative frames Astrana Health as 9.2% overvalued at a $36.00 fair value, the SWS DCF model points in the opposite direction. On that cash flow view, Astrana Health at $39.30 sits roughly 69% below an estimated fair value of $127, which is a large gap for investors to weigh.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Astrana Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between risk and reward, this is the moment to look through the numbers yourself and decide where you stand, starting with 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If Astrana Health has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target resilience first by scanning companies with strong finances and low leverage through our solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for quality at a discount by checking stocks that screen well on value and fundamentals using our screener containing 21 high quality undiscovered gems.
• Prioritise sleep-at-night holdings by filtering for companies with muted risk profiles via our 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.